Evidence map›Paper›PMID 36381627›Full record

ArticleOpen forum infectious diseases2022

Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for Infection and Infectious Viral Shedding.

Sujata Mathur, Michelle C Davidson, Khamal Anglin, Scott Lu, Sarah A Goldberg, Miguel Garcia-Knight, Michel Tassetto, Amethyst Zhang, Mariela Romero, Jesus Pineda-Ramirez and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Sujata MathurDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Michelle C DavidsonFrancis I. Proctor Foundation, University of California, San Francisco, California, USA.
Khamal AnglinInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Miguel Garcia-KnightDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Michel TassettoDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Amethyst ZhangDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Mariela RomeroInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Jesus Pineda-RamirezInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Ruth Diaz-SanchezInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Paulina RugartInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Jessica Y ChenInstitute for Global Health Sciences, University of California, San Francisco, California, USA.
Kevin DonohueSchool of Medicine, University of California, San Francisco, California, USA.
Joshua R ShakSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Ahmed ChennaLabcorp-Monogram Biosciences, South San Francisco, California, USA.
John W WinslowLabcorp-Monogram Biosciences, South San Francisco, California, USA.
Christos J PetropoulosLabcorp-Monogram Biosciences, South San Francisco, California, USA.
Brandon C YeeLabcorp-Monogram Biosciences, South San Francisco, California, USA.
Jeremy LambertQuanterix Laboratories, Billerica, Massachusetts, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
George W RutherfordDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA.
Michael J PelusoDivision of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA.
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
University of California, San Francisco · USGlobal Brain Health Institute · USLabCorp (United States) · USSan Francisco Foundation · USSan Francisco VA Medical Center · USQuanterix (United States) · US

Funding

Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
VAccine failure: natural history and determinants of post-vaccination Covid-19I01CX002417 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI John Daniel Kelly, Salomeh Keyhani · 2022 to 2026
–
NIAID NIH HHS K23 AI146268NIAID NIH HHS L30 AI126521NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

Background: SARS-CoV-2 nucleocapsid antigen can be detected in plasma, but little is known about its performance as a diagnostic test for acute SARS-CoV-2 infection or infectious viral shedding among nonhospitalized individuals. Methods: We used data generated from anterior nasal and blood samples collected in a longitudinal household cohort of SARS-CoV-2 cases and contacts. Participants were classified as true positives if polymerase chain reaction (PCR) positive for SARS-CoV-2 and as true negatives if PCR negative and seronegative. Infectious viral shedding was determined by the cytopathic effect from viral culture. Stratified by 7 days after symptom onset, we constructed receiver operating characteristic (ROC) curves to describe optimized accuracy (Youden index), optimized sensitivity, and specificity. Results: Of 80 participants, 58 (73%) were true positives while 22 (27%) were true negatives. Using the manufacturer's cutoff of 1.25 pg/mL for evaluating infection, sensitivity was higher from 0 to 7 days (77.6% [95% confidence interval {CI}, 64%-88.2%]) than from 8 to 14 days (43.2% [95% CI, 31.1%-54.5%]) after symptom onset; specificity was unchanged at 100% (95% CI, 88.1%-100%). This test had higher sensitivity (100% [95% CI, 88.4%-100%]) and lower specificity (65% [95% CI, 40.8%-84.6%]) for infectious viral shedding as compared with infection, particularly within the first week of symptom onset. Although the presence of N-antigen correlated with infectious viral shedding ( Conclusions: We found that this SARS-CoV-2 N-antigen test was highly sensitive for detecting early but not late infectious viral shedding, making it a viable screening test for community-dwelling individuals to inform isolation practices.

Indexed as

bloodinfectiousnessinfectivitynucleocapsid antigenperformance

Identifiers

PMID36381627
PMCPMC9620332
OpenAlexW4307137838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.